Details

Autor(en) / Beteiligte

• LENGFELDER, E
• HAFERLACH, C
• KERN, W
• REICHLE, A
• SERVE, H
• BERDEL, W. E
• BRAESS, J
• SPIEKERMANN, K
• WÖRMANN, B
• SAUERLAND, M.-C
• HEINECKE, A
• HIDDEMANN, W
• SAUSSELE, S
• HEHLMANN, R
• BÜCHNER, T
• HAFERLACH, T
• SCHULTHEIS, B
• SCHNITTGER, S
• LUDWIG, W.-D
• STAIB, P
• AUL, C
• GRÜNEISEN, A

Titel

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

Ist Teil von

• Leukemia, 2009-12, Vol.23 (12), p.2248-2258

Ort / Verlag

Avenel, NJ: Nature Publishing Group

Erscheinungsjahr

2009

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The objective of this study for newly diagnosed acute promyelocytic leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy including high dose ara-C (HD) and all-trans retinoic acid (ATRA) followed by consolidation and 3 years maintenance therapy. In contrast to APL studies stratifying therapy according to pretreatment white blood cell (WBC) count < and > or =10 x 10(9)/l (low/intermediate and high risk according to the Sanz score), our patients received uniform therapy. From 1994 to 2005, 142 patients (age, 16-60 years) were enrolled. In the low/intermediate (n=105) vs high (n=37) WBC group, the rates of complete remission were 95.2 vs 83.8%, of induction death were 4.8 vs 16.2% (P=0.05) and of molecular remission were 87.5 vs 91.3% (P=1). Long-term overall survival was 84.4 vs 73.0% (P=0.12), event free survival was 78.3 vs 67.3% (P=0.11), relapse free survival was 82.1 vs 80.0% (P=0.83) and the cumulative incidence of relapse was 7.4 vs 11.4% (P=0.46). No relapse or death occurred after 4.7 years. ATRA and intensified chemotherapy including HD ara-C followed by prolonged maintenance therapy reduced the relapse risk in high risk patients. Pretreatment WBC count > or =10 x 10(9)/l count was no relevant prognostic factor for relapse.